Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma.

Eissa, Ibrahim H; Ibrahim, Mohammed K; Metwaly, Ahmed M; Belal, Amany; Mehany, Ahmed B M; Abdelhady, Alsayed A; Elhendawy, Mostafa A; Radwan, Mohamed M; ElSohly, Mahmoud A; Mahdy, Hazem A

Eissa, Ibrahim H; Ibrahim, Mohammed K; Metwaly, Ahmed M; Belal, Amany; Mehany, Ahmed B M; Abdelhady, Alsayed A; Elhendawy, Mostafa A; Radwan, Mohamed M; ElSohly, Mahmoud A; Mahdy, Hazem A.

Afiliación

Eissa IH; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt. Electronic address: Ibrahimeissa@azhar.edu.eg.
Ibrahim MK; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt.
Metwaly AM; Pharmacognosy Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt.
Belal A; Medicinal Chemistry Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt.
Mehany ABM; Zoology Department, Faculty of Science, Al-Azhar University, Cairo 11884, Egypt.
Abdelhady AA; Department of Anatomy, Faculty of Medicine, Helwan University, Cairo, Egypt.
Elhendawy MA; National Center for Natural Products Research, University of Mississippi, MS 38677, USA; Department of Agriculture Chemistry, Faculty of Agriculture, Damietta University, Damietta, Egypt.
Radwan MM; National Center for Natural Products Research, University of Mississippi, MS 38677, USA; Department of Pharmacognosy, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
ElSohly MA; National Center for Natural Products Research, University of Mississippi, MS 38677, USA; Department of Pharmaceutics and Drug Delivery, University of Mississippi, University, MS 38677, USA.
Mahdy HA; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt. Electronic address: hazem_hady2001@azhar.edu.eg.

Bioorg Chem ; 107: 104532, 2021 02.

Article en En | MEDLINE | ID: mdl-33334586

Asunto(s)

Antineoplásicos/uso terapéutico; Carcinoma Hepatocelular/tratamiento farmacológico; Neoplasias Hepáticas/tratamiento farmacológico; Inhibidores de Proteínas Quinasas/uso terapéutico; Quinazolinonas/uso terapéutico; Receptor 2 de Factores de Crecimiento Endotelial Vascular/antagonistas & inhibidores; Animales; Antineoplásicos/síntesis química; Antineoplásicos/metabolismo; Antineoplásicos/farmacocinética; Apoptosis/efectos de los fármacos; Carcinoma Hepatocelular/patología; Proliferación Celular/efectos de los fármacos; Puntos de Control de la Fase G1 del Ciclo Celular/efectos de los fármacos; Puntos de Control de la Fase G2 del Ciclo Celular/efectos de los fármacos; Células Hep G2; Humanos; Neoplasias Hepáticas/patología; Masculino; Simulación del Acoplamiento Molecular; Estructura Molecular; Inhibidores de Proteínas Quinasas/síntesis química; Inhibidores de Proteínas Quinasas/metabolismo; Inhibidores de Proteínas Quinasas/farmacocinética; Quinazolinonas/síntesis química; Quinazolinonas/metabolismo; Quinazolinonas/farmacocinética; Ratas; Relación Estructura-Actividad; Receptor 2 de Factores de Crecimiento Endotelial Vascular/metabolismo

Palabras clave

Anticancer; Apoptosis; In vivo studies; Liver cancer; Molecular docking; Quinazolin-4(3H)-one; VEGFR-2 inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Receptor 2 de Factores de Crecimiento Endotelial Vascular / Inhibidores de Proteínas Quinasas / Quinazolinonas / Neoplasias Hepáticas / Antineoplásicos Tipo de estudio: Prognostic_studies Idioma: En Revista: Bioorg Chem Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google